Chinook names Oxtoby head of commercial

Kidney disease company Chinook Therapeutics Inc. (NASDAQ:KDNY) hired Andrew Oxtoby as chief commercial officer (CCO). Oxtoby was president and CEO of Aimmune Therapeutics Inc., which was acquired by Nestlé Health Science in 2020. Previously, he held several roles of increasing responsibilities at Eli Lilly and Co. (NYSE:LLY) for 16 years. 

Asabys Partners named Principal Sylvain Sachot and Investment Director Guillem Masferrer partners. The VC firm also announced the first close of its second fund, Sabadell Asabys Health Innovation Investments II, at €100 million ($106 million), with a goal to reach €200 million this year. SAHII will invest in 12 to 15 health tech and biopharma companies across the EU, Israel, U.K. and the U.S...